Paclitaxel 80 mg/m2 weekly

DRUG3 trials

Sponsors

Boehringer Ingelheim, BioInvent International AB, AntiCancer Research Jamaica

Conditions

Advanced MalignanciesBreast NeoplasmsMelanomaMetastatic Triple-negative Breast CancerOvarian CancerT-cell LymphomaTriple Negative Breast Cancer

Phase 1

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

RecruitingNCT04752826

BioInvent International ABAdvanced Malignancies, Melanoma, Ovarian Cancer +1

Start: 2021-01-25End: 2028-12-31Target: 250Updated: 2026-09-18

Phase 2

LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures

CompletedNCT01271725

Boehringer IngelheimBreast Neoplasms

Start: 2011-05-24End: 2017-03-13Updated: 2019-06-17

Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer

Not yet recruitingNCT07528768

AntiCancer Research JamaicaMetastatic Triple-negative Breast Cancer, Triple Negative Breast Cancer

Start: 2026-06-01End: 2034-06-01Target: 750Updated: 2026-04-14

Related Papers

BI-1808 + pembrolizumab: Responses to a chemotherapy-free regimen in advanced ovarian cancer.

Journal of Clinical Oncology2026-05-27

19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab.

Journal of Clinical Oncology2024-06-013 citations

Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial

Breast Cancer Research and Treatment2022-02-0912 citations